AHA26: AI plaque analysis bests standard of care in suspected CAD patients
Cleerly’s highlighted that its PARAMOUNT trial demonstrated medical management and interventional treatment benefits in suspected CAD patients.
Cleerly’s highlighted that its PARAMOUNT trial demonstrated medical management and interventional treatment benefits in suspected CAD patients.
The British government will now change up AI-enabled medical device regulation to encourage innovation with the appropriate guardrails.
The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare,...
Drug delivery’s next bottleneck isn’t innovation, it’s industrial capacity
Australia starts investigation into OpenAI Medicare breach
Industry partnership will determine the success of the transition to low-GWP pMDIs
UK government champions healthtech through new NHS access programme